{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Testosterone",
        "LIAISON\u00ae Testosterone Control Set"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K122793",
    "Predicate Device Reference 510(k) Number(s)": [
        "K093421",
        "K090541"
    ],
    "Regulatory Class": "Class I, reserved",
    "Product Code(s)": [
        "CDZ",
        "JJX"
    ],
    "Summary Letter Date": "January 25, 2013",
    "Summary Letter Received Date": "December 17, 2012",
    "Submission Date": "December 14, 2012",
    "Regulation Number(s)": [
        "21 CFR 862.1680",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Testosterone test system",
        "Quality Control Material, Clinical Chemistry"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Testosterone"
    ],
    "Specimen Type(s)": [
        "Serum",
        "EDTA Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Direct competitive immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control Set",
        "Reagent Kit",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae Testosterone assay and Control Set for quantitative measurement of testosterone in human serum and plasma using CLIA on the LIAISON\u00ae Analyzer.",
    "Indications for Use Summary": "Quantitative determination of testosterone in human serum and plasma to aid diagnosis and treatment of male sex hormone disorders including hypogonadism, puberty disorders, impotence, and in females, hirsutism and virilization due to tumors, polycystic ovaries, and adrenogenital syndromes; Control Set for monitoring assay accuracy and precision.",
    "fda_folder": "Clinical Chemistry"
}